Weekly Digest - June 2025

Weekly Digest - June 2025

17 June 2025: FDA grants orphan drug designation to Medicovestor’s first-in-class ADC for pancreatic cancer

  • The FDA has granted Orphan Drug Designation to Medicovestor’s lead candidate, ADoBind MC001, for treating pancreatic cancer, a disease with limited therapies and poor survival rates
  • ADoBind MC001 represents a new class of chemoimmunotherapy ADCs that combine targeted payload delivery with immune system engagement for enhanced tumor-killing effect
  • Medicovestor is currently progressing ADoBind MC001 through IND-enabling studies, with a Phase 1 clinical trial expected to begin in early 2026

For full story click  here

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share
Home